FDA Panel Rejects Intellipharmaceutics' Opioid For Missing Data, Blue Dye Safety Concern

 
• By Brenda Sandburg
FDASignBldg21Entrance_1200x675

More from US FDA Performance Tracker

More from Regulatory Trackers